viewCynata Therapeutics Ltd

HC Wainwright repeats 'buy' on Cynata as ongoing trial is cleared by data safety monitoring board

Analyst Raghuram Selvaraju repeated a 'buy' stance and targets A$1.50 for the shares

Aussie-listed Cynata is a stem cell group

Broker HC Wainwright is bullish on stem cell group Cynata Therapeutics Ltd (ASX:CYP) following encouraging early findings from clinical trials of its CYP-001 treatment for steroid-resistant graft-versus-host disease.

The data safety monitoring board has now recommended that the group's clinical trial progress to a second Cohort of patients.

READ: Cynata Therapeutics wins U.S. patent for stem cell technology

Analyst Raghuram Selvaraju repeated a 'buy' stance and targets A$1.50 for the shares, which is more than double where they are now - at A$0.64 (up 8.47%).

"All eight participants in Cohort A have demonstrated at least a partial response, which is defined as an improvement in the severity of their graft-vs. host disease (GvHD) by at least one grade vs. baseline. In addition, thus far no treatment-related serious adverse events (SAEs) or safety concerns have been observed. Patient enrollment for Cohort B is now open at seven trial sites in the UK and Australia," said the analyst.

In Cohort B, it is planned that a further eight participants would receive two CYP-001 infusions each at a higher dose level - up to a maximum of 200M cells per infusion, the broker added.

Quick facts: Cynata Therapeutics Ltd

Price: - -

Market: ASX
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cynata Therapeutics Ltd named herein, including the promotion by the Company of Cynata Therapeutics Ltd in any Content on the Site, the Company...


Cynata Therapeutics meets with New York investors following good news from...

Cynata Therapeutics Ltd (ASX:CYP) (OTCMKTS:CYYNF) CEO Ross Macdonald tells Proactive's Christine Corrado the cell therapy company has met the clinical endpoints of a Phase 1 trial of its Cymerus mesenchymal stem cell (MSC) product candidate in people with steroid-resistant acute...

on 09/10/2018

2 min read